{
    "score": [
        1.0
    ],
    "extracted": [
        4
    ],
    "abstract": [
        "psivida getting somewhat favorable press coverage , analysis finds ."
    ],
    "id": "56131.train",
    "article": [
        "media coverage about psivida has trended somewhat positive on sunday , according to accern sentiment . accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time . accern ranks coverage of companies on a scale of negative one to positive one , with scores nearest to one being the most favorable . psivida earned a media sentiment score of 0.12 on accern 's scale . accern also assigned news coverage about the company an impact score of 46.2789315696695 out of 100 , indicating that recent news coverage is somewhat unlikely to have an impact on the stock 's share price in the next few days . ",
        "psdv has been the topic of several recent research reports . hc wainwright restated a `` buy '' rating and set a $ 5.00 target price on shares of psivida in a research report on wednesday , november 8th . laidlaw initiated coverage on shares of psivida in a research report on wednesday , november 8th . they set a `` buy '' rating and a $ 5.00 target price on the stock . b. riley set a $ 5.00 target price on shares of psivida and gave the company a `` buy '' rating in a research report on monday , december 4th . ",
        "finally , valuengine cut shares of psivida from a `` sell '' rating to a `` strong sell '' rating in a research report on friday , december 1st . one equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company 's stock . psivida presently has an average rating of `` buy '' and a consensus target price of $ 7.57 . shares of psivida traded down $ 0.04 during midday trading on friday , hitting $ 1.23 . 458,165 shares of the stock traded hands , compared to its average volume of 506,522 . ",
        "psivida has a 52-week low of $ 1.03 and a 52-week high of $ 2.45 . psivida last posted its quarterly earnings data on tuesday , november 7th . the company reported earnings per share for the quarter , hitting the zacks ' consensus estimate of . psivida had a negative net margin of 226.31 % and a negative return on equity of 139.56 % . the company had revenue of $ 0.39 million for the quarter , compared to analyst estimates of $ 0.74 million . sell-side analysts anticipate that psivida will post -0.58 earnings per share for the current fiscal year . ",
        "trademark violation warning : `` psivida getting somewhat favorable press coverage , analysis finds '' was first posted by daily political and is the sole property of of daily political . if you are viewing this news story on another publication , it was illegally stolen and reposted in violation of u. s. & international trademark & copyright legislation . the correct version of this news story can be read at company profilepsivida corp. . develops drug delivery products primarily for the treatment of chronic eye diseases . the company operates through the biotechnology sector segment . the company has developed three products for treatment of back-of-the-eye diseases , which include medidur for posterior segment uveitis , its lead product candidate that is in pivotal phase iii clinical trials ; iluvien for diabetic macular edema , its lead licensed product that is sold in the united states and european union countries , and retisert . "
    ]
}